Catalysts / RNAC
Upcoming FDA decisions and readouts we track for Cartesian Therapeutics, each with the filing that announced it.
FreeBioList tracks 4 upcoming catalysts for Cartesian Therapeutics (RNAC, listed on Nasdaq). All of them concern Descartes-08 (Myasthenia gravis (mRNA CAR-T); Myositis; Juvenile dermatomyositis (paediatric); Myasthenia gravis).
First on the list: the Phase 3 readout for Descartes-08 (Myasthenia gravis (mRNA CAR-T)), guided by the company to Q1 2027. The furthest-out event tracked is Mid 2027. By stage, the upcoming rows are 1 Phase 1/2 readout, 1 Phase 2 readout, 1 Phase 3 readout and 1 Regulatory submission.
All 4 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: How to read a Phase 3 topline readout; Clinical trial phases explained: Phase 1 to Phase 4; NDA vs BLA: the two kinds of US drug application.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Cartesian Therapeutics RNAC · Nasdaq | Descartes-08 | Myasthenia gravis (mRNA CAR-T) | Q1 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Cartesian Therapeutics RNAC · Nasdaq | Descartes-08 | Myositis | H1 2027 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Cartesian Therapeutics RNAC · Nasdaq | Descartes-08 | Juvenile dermatomyositis (paediatric) | H1 2027 company guidance |
Phase 1/2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Cartesian Therapeutics RNAC · Nasdaq | Descartes-08 | Myasthenia gravis | Mid 2027 company guidance |
Regulatory submission | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList